Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives

Annals of Oncology, Mar 2012

The effectiveness of platinum re-treatment in relapsed ovarian cancer depends on relapse-free/treatment-free intervals. Platinum agents can be effectively readministered to platinum-sensitive patients (relapsing >12 months after platinum), but efficacy is lower in partially platinum-sensitive (PPS) disease (relapsing 6–12 months after platinum). There is no clear standard treatment challenging PPS patients. Survival data in this subset with chemotherapy combinations such as pegylated liposomal doxorubicin (PLD) plus carboplatin or gemcitabine plus PLD are available from phase II trials ranging from 16 to 21 months. Recent results from OVA-301 phase III randomized trial evaluating trabectedin plus PLD showed the longest median overall survival ever reported in PPS patients (23 months). Subsequent chemotherapy (including platinum-based regimens) was administered later and survival in patients receiving third-line platinum was longer in patients treated with trabectedin plus PLD compared with those treated with PLD alone. These results suggest that prolonging platinum-free interval (PFI) with an effective non-platinum regimen improves outcome with subsequent third-line platinum treatment. An ongoing phase III trial (INOVATYON) aims to demonstrate if the results observed with trabectedin plus PLD in PPS patients are due to PFI extension, and if PFI extension with non-platinum combination prolongs response to subsequent platinum and survival in this population.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://annonc.oxfordjournals.org/content/23/3/556.full.pdf

Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives

J. Sehouli 2 V. Alfaro 1 A. Gonza lez-Martn 0 0 Department of Medical Oncology, Centro Oncologico MD Anderson International , Madrid, Spain 1 Clinical R&D , PharmaMar, Colmenar Viejo, Madrid 2 Department of Obstetrics and Gynecology, Charite University Hospital , Berlin, Germany The effectiveness of platinum re-treatment in relapsed ovarian cancer depends on relapse-free/treatment-free intervals. Platinum agents can be effectively readministered to platinum-sensitive patients (relapsing >12 months after platinum), but efficacy is lower in partially platinum-sensitive (PPS) disease (relapsing 6-12 months after platinum). There is no clear standard treatment challenging PPS patients. Survival data in this subset with chemotherapy combinations such as pegylated liposomal doxorubicin (PLD) plus carboplatin or gemcitabine plus PLD are available from phase II trials ranging from 16 to 21 months. Recent results from OVA-301 phase III randomized trial evaluating trabectedin plus PLD showed the longest median overall survival ever reported in PPS patients (23 months). Subsequent chemotherapy (including platinum-based regimens) was administered later and survival in patients receiving third-line platinum was longer in patients treated with trabectedin plus PLD compared with those treated with PLD alone. These results suggest that prolonging platinum-free interval (PFI) with an effective non-platinum regimen improves outcome with subsequent third-line platinum treatment. An ongoing phase III trial (INOVATYON) aims to demonstrate if the results observed with trabectedin plus PLD in PPS patients are due to PFI extension, and if PFI extension with non-platinum combination prolongs response to subsequent platinum and survival in this population. - introduction Platinum-containing regimens are currently the mainstay of initial treatment of ovarian cancer and platinum-sensitive relapsed disease. In relapsed ovarian cancer, the effectiveness of platinum re-treatment depends on the relapse-free/treatmentfree intervals (Table 1). Platinum agents can be effectively readministered to patients with disease relapsing >12 months after completion of a platinum regimen (i.e. patients with platinum-sensitive disease), with response rates ranging from 30% to 60%, but ovarian cancer that relapses 612 months after platinum treatment has lower response to platinum rechallenge (25%30%) [36] and is considered partially platinum sensitive (PPS). These categories are based on empirical observations made 20 years ago. Ovarian cancer relapsing in the 612 months time frame has also been defined as intermediate platinum sensitive or simply as chemotherapy sensitive because new non-platinum agents and combinations are being identified as active in this setting [7, 8]. The use of non-platinum agents in relapsed ovarian cancer to prolong platinum-free interval (PFI) has gained interest recently, as the likelihood of response to platinum reinduction at next relapse may increase [9]. The acquired resistance to platinum is an unstable phenotype over time [10]. Thus, in vitro studies [11] have shown platinum resistance as an unstable, inducible, and perhaps reversible phenomenon. In vitro [11] and clinical data [9, 12, 13] suggest that PFI extension in patients with relapsed PPS ovarian cancer through intercalation of a nonplatinum therapy before platinum-based regimens at further progression could be beneficial from a clinical point of view. It has been hypothesized that platinum (or chemotherapy) sensitivity could be restored using a PFI prolongation strategy [6, 7]. Furthermore, most patients with recurrent ovarian cancer will die due to tumor progression; therefore, the definition of the best therapeutic index for these patients including not only tumor and symptom control but also the toxicity profile is one of the most challenging topics in gynecologic oncology. Rechallenge with platinum-based combinations is not only associated with risk of development of severe allergy [1] but also polyneuropathy and alopecia [14]. Based on these considerations, both from the clinical and the scientific perspective, the use of platinum as the first treatment option in patients with PPS relapse may be questioned. Limited information exists in this regard as most clinical trials with newer agents have been either nonrandomized phase II studies or phase III randomized studies conducted in a heterogeneous population of women, sometimes even including patients with platinum-resistant disease. Unfortunately, phase III studies of combination regimens compared with platinum monotherapy and others comparing various non-platinum single agents usually have not reported separate data for the PPS subset. Therefore, interpretation of the activity of the newer agents in the PPS population is often difficult, and this may affect decision making in clinical practice [5]. results of clinical trials evaluating combination regimens and including patients with PPS ovarian canc (...truncated)


This is a preview of a remote PDF: https://annonc.oxfordjournals.org/content/23/3/556.full.pdf

J. Sehouli, V. Alfaro, A. González-Martín. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives, Annals of Oncology, 2012, pp. 556-562, 23/3, DOI: 10.1093/annonc/mdr321